Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied
Axsome Therapeutics, Inc. is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. AXSM's Q1 revenues grew 57% year-on-year to $191m, but both Auvelity and Sunosi saw sequential sales declines. Management's peak revenue targets—over $18bn across the portfolio—appear highly ambitious given current product performance and competitive dynamics.
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings
Although the revenue and EPS for Axsome (AXSM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago.
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued
Axsome Therapeutics, Inc. delivered 66% full-year 2025 revenue growth to $638.5M, driven by Auvelity and Sunosi, but remains loss-making. Despite a robust pipeline and upcoming catalysts, I downgrade AXSM to Hold due to valuation risks and commercial uncertainties in competitive markets. AXSM's 2030 revenue could reach ~$3.5B in a best-case scenario, but achieving blockbuster status for key assets like Sunosi and Symbravo remains uncertain.
